Zobrazeno 1 - 10
of 770
pro vyhledávání: '"Vingiani A"'
Autor:
Matteo Bonatti, Riccardo Valletta, Valentina Corato, Tommaso Gorgatti, Andrea Posteraro, Vincenzo Vingiani, Fabio Lombardo, Giacomo Avesani, Andrea Mega, Giulia A. Zamboni
Publikováno v:
Insights into Imaging, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Focal liver lesions are frequently encountered during imaging studies, and hemangiomas represent the most common solid liver lesion. Liver hemangiomas usually show characteristic imaging features that enable characterization without the need
Externí odkaz:
https://doaj.org/article/5df620700315456292c6ce0ae1c1c50e
Autor:
G. M. Sarcinelli, L. Varinelli, S. Ghislanzoni, F. Padelli, D. Lorenzini, A. Vingiani, M. Milione, M. Guaglio, S. Kusamura, M. Deraco, G. Pruneri, M. Gariboldi, D. Baratti, I. Bongarzone
Publikováno v:
Cancer & Metabolism, Vol 12, Iss 1, Pp 1-13 (2024)
Abstract Even with systemic chemotherapy, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC), peritoneal metastases (PM) remain a common site of disease progression for colorectal cancer (CRC) and are frequently associ
Externí odkaz:
https://doaj.org/article/a28edbf2551f4e6394fb9ee6e22f7c56
Autor:
Moregola, Annalisa, Bonacina, Fabrizia, Vingiani, Giovanni Battista, Frapolli, Roberta, Turrini, Renato, Norata, Giuseppe Danilo
Publikováno v:
In Pharmacological Research November 2024 209
Autor:
Serena Di Cosimo, Sara Pizzamiglio, Chiara Maura Ciniselli, Valeria Duroni, Vera Cappelletti, Loris De Cecco, Cinzia De Marco, Marco Silvestri, Maria Carmen De Santis, Andrea Vingiani, Biagio Paolini, Rosaria Orlandi, Marilena Valeria Iorio, Giancarlo Pruneri, Paolo Verderio
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract In clinical trials evaluating antibody-conjugated drugs (ADCs), HER2-low breast cancer is defined through protein immunohistochemistry scoring (IHC) 1+ or 2+ without gene amplification. However, in daily practice, the accuracy of IHC is comp
Externí odkaz:
https://doaj.org/article/d7df224a01ee4e5988733bfc39acbfb0
Autor:
Gennaro, Massimiliano, Mariani, Luigi, Palassini, Elena, Stacchiotti, Silivia, Sangalli, Claudia, Listorti, Chiara, Vingiani, Andrea, Cortinovis, Umberto, Collini, Paola, Allajbej, Albina, Fiore, Marco, Casali, Paolo G., Folli, Secondo, Gronchi, Alessandro
Publikováno v:
In European Journal of Surgical Oncology December 2024 50(12)
Publikováno v:
In Science of the Total Environment 10 July 2024 933
Autor:
Abou-Foul, Ahmad K, Henson, Christina, Chernock, Rebecca D, Huang, Shao Hui, Lydiatt, William M, McDowell, Lachlan, O’Sullivan, Brian, Perez-Ordonez, Bayardo, Robinson, Max, Nankivell, Paul C, Ruiz-Bravo, Elena, Chiosea, Simion I, Green, Tina M, Hunter, Keith D, Hwang, Jacqueline SG, Koljenovic, Senada, Koppes, Sjors A, Larsen, Stine R, Lo, Anthony W I, Costes-Martineau, Valérie, Mittal, Neha, Mori, Taisuke, Nagao, Toshitaka, Panayiotides, Ioannis G, Pinto, Clóvis A L, Scheckenbach, Kathrin, Seethala, Raja R, Ulhøi, Benedicte P, Vingiani, Andrea, Zhang, Yan, Yom, Sue S, Mehanna, Hisham *
Publikováno v:
In The Lancet Oncology July 2024 25(7):e286-e296
Autor:
Ciniselli, Chiara M., Verderio, Paolo, Baili, Paolo, Sant, Milena, Pizzamiglio, Sara, Duroni, Valeria, de Braud, Filippo G., Folli, Secondo, Scaperrotta, Gianfranco, De Santis, Maria C., Apolone, Giovanni, De Marco, Cinzia, Vingiani, Andrea, Cappelletti, Vera, Pruneri, Giancarlo, Di Cosimo, Serena
Publikováno v:
In Clinical Breast Cancer August 2024
Autor:
Nerina Denaro, Lisa Licitra, Marco Merlano, Francesco Perri, Paolo Bossi, Cristina Gurizzan, Federica Perrone, Athanassios Argiris, Loris De Cecco, Stefano Cavalieri, Mara Serena Serafini, Federico Pistore, Deborah Lenoci, Silvana Canevari, Mario Airoldi, Maria Cossu Rocca, Primoz Strojan, Cvetka Grasic Kuhar, Andrea Vingiani, Maria Grazia Ghi, Alessandra Cassano, Giacomo Allegrini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit in clinical trials is variable and h
Externí odkaz:
https://doaj.org/article/b9740be0719d4304a7e872232992bfd0
Autor:
Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani, Federico Nichetti, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Chiara Corti, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Daniele Presti, Caterina Sposetti, Carlo Alberto Giorgi, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Daniele Generali, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2− aBC). Objectives: While CDK4/6i
Externí odkaz:
https://doaj.org/article/997ec44c91b244349cd2462f6a583683